Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEnterprise ValueMarket CapitalizationPrice
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

China SXT Pharmaceuticals (SXTC) Enterprise Value (2019 - 2026)

China SXT Pharmaceuticals has reported Enterprise Value over the past 8 years, most recently at -$21.2 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 14.5% year-over-year to -$21.2 million; the TTM value through Sep 2025 reached -$21.2 million, down 14.5%, while the annual FY2025 figure was -$18.1 million, 50.11% down from the prior year.
  • Enterprise Value for Q3 2025 was -$21.2 million at China SXT Pharmaceuticals, down from -$18.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$3.0 million in Q3 2022 and troughed at -$31.3 billion in Q3 2021.
  • A 5-year average of -$3.1 billion and a median of -$16.5 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: crashed 302416.82% in 2021 and later surged 99.99% in 2022.
  • Year by year, Enterprise Value stood at -$31.3 billion in 2021, then surged by 99.99% to -$3.0 million in 2022, then tumbled by 284.6% to -$11.5 million in 2023, then plummeted by 61.47% to -$18.5 million in 2024, then dropped by 14.5% to -$21.2 million in 2025.
  • Business Quant data shows Enterprise Value for SXTC at -$21.2 million in Q3 2025, -$18.1 million in Q1 2025, and -$18.5 million in Q3 2024.